Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission

Stanford University200 enrolled

Overview

Evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation for AML.

To use high dose chemotherapy with autologous stem cell rescue to try to increase the chance of long term control and cure of the disease.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

200

Sex: ALLMin age: 16 YearsMax age: 69 Years

Medical Language ↔ Plain English

Inclusion Criteria:- must be in remission * adequate organ function Exclusion Criteria:- prior MDS * active infection * liver disease

Stanford University School of Medicine

Stanford, California, United States

Disease free survival (DFS)

Transplant related mortality (TRM)

Toxicity

Adequacy of cell collections

Engraftment kinetics

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.